Evidence-based research and foresight for leaders navigating the systemic transformation of global markets.
Political shifts in China, care site migration, supply chain realignment, GLP-1 therapies, and platform-based competition are redefining the medical technology industry. This analysis explores the strategic implications for global medtech leaders.
Medtech in 2026 is being reshaped by China's VBP expansion, outpatient migration, supply chain pressures, GLP-1 therapies, and platform competition.
Explore the key medtech trends for 2026, including pricing pressure, care migration, supply chain resilience, GLP-1 impacts, and platform competition. Strategic insights for executives and investors.
An analysis of the five medtech trends defining 2026—China's procurement expansion, the shift to outpatient care, supply chain resilience, GLP-1 therapies, and platform-based competition—and their strategic implications for global businesses.
An executive analysis of five key medtech trends in 2026 — China's VBP expansion, outpatient care migration, supply chain restructuring, GLP-1 therapy impacts, and platform-based competition — and their implications for global manufacturers.
An executive analysis of the five medtech trends—China's VBP expansion, outpatient shift, supply chain pressures, GLP-1 therapy impact, and enabling technologies—reshaping strategy, competition, and investment.